1. Metabolic Enzyme/Protease
    GPCR/G Protein
  2. Angiotensin-converting Enzyme (ACE)
    Angiotensin Receptor
  3. Angiotensin 1-7

Angiotensin 1-7 (Synonyms: Angiotensin-(1-7); Ang-(1-7))

Cat. No.: HY-12403 Purity: 99.61%
Handling Instructions

Angiotensin (1-7) inhibits purified canine angiotensin converting enzyme (ACE) activity with an IC50 of 0.65 μM.

For research use only. We do not sell to patients.

Angiotensin 1-7 Chemical Structure

Angiotensin 1-7 Chemical Structure

CAS No. : 51833-78-4

Size Price Stock Quantity
10 mM * 1 mL in Water USD 95 In-stock
Estimated Time of Arrival: December 31
5 mg USD 60 In-stock
Estimated Time of Arrival: December 31
10 mg USD 96 In-stock
Estimated Time of Arrival: December 31
25 mg USD 144 In-stock
Estimated Time of Arrival: December 31
50 mg USD 252 In-stock
Estimated Time of Arrival: December 31
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Other Forms of Angiotensin 1-7:

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Angiotensin (1-7) inhibits purified canine angiotensin converting enzyme (ACE) activity with an IC50 of 0.65 μM.

IC50 & Target

IC50: 0.65 μM (ACE)[1]

In Vitro

Angiotensin 1-7 (Ang 1-7) acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide (NO). Angiotensin (1-7) augments the vasodilation induced by bradykinin (BK) in a concentration-dependent manner in rings preconstricted with the thromboxane analog U46619. The EC50 of BK (2.45±0.51 nM versus 0.37±0.08 nM) is shifted leftward by 6.6-fold in the presence of 2 μM concentration of Angiotensin (1-7). The BK-induced relaxation response is augmented by Angiotensin (1-7) (0.1 to 2 μM) in a dose-dependent manner. At a concentration of 2 μM Angiotensin (1-7), relaxation to BK is increased 92% compared to BK alone (41±4.4% versus 92±2.5%, P<0.01). Angiotensin (1-7) possesses novel biological functions that are distinct from Ang II. In contrast to Ang II, Angiotensin (1-7) is not a dipsogen or an aldosterone secretagogue, but similar to Ang II, it stimulates the release of vasopressin, prostaglandins, and NO. Angiotensin (1-7) counteracts several actions of Ang II. In both canine and porcine coronary arteries, Angiotensin (1-7) causes vasodilation, while Ang II divergently constricts the coronary arteries. Angiotensin (1-7) inhibits cultured vascular smooth muscle cell growth, whereas equal molar concentration of Ang II stimulates cell growth[1]. Angiotensin 1-7 (Ang 1-7) abrogates the methylglyoxal-modified albumin (MGA)-stimulated myofibroblast phenotype by inhibiting the chronic stimulation of the TGF-β-ERK pathway in NRK-52E cells[2].

In Vivo

A seven fold decrease in the plasma level of Angiotensin 1-7 (Ang 1-7) is demonstrated in dextran sulfate sodium (DSS) treated mice compare to untreated (UT) group at day 7 post colitis induction. On the other hand, a significant increase in Ang 1-7 is observed in colon homogenates of DSS treated mice at day 7 (0.09 ng/mL) compare to UT mice (0.04 ng/mL)[3]. The ovariectomized (OV) female Wistar-rats receive estradiol (500 μg/kg/week) or vehicle for two weeks. The animals are anesthetized, cannulated, and the responses including mean arterial pressure, renal blood flow (RBF), and renal vascular resistance at the constant level of renal perfusion pressure to graded infusion of Angiotensin 1-7 (Ang 1-7) at 0, 100 and 300 ng/kg/min are determined in OV and OV estradiol-treated (OVE) rats, treated with vehicle or MasR antagonist; A779. RBF response to Ang 1-7 infusion increased dose-dependently in vehicle (Pdose<0.001) and A779-treated (Pdose<0.01) animals. However, when MasR is blocked, the RBF response to Ang 1-7 significantly increases in OV animals compare with OVE rats (P<0.05). When estradiol is limited by ovariectomy, A779 increases RBF response to Angiotensin (1-7) administration, while this response is attenuated in OVE animals[4].

Clinical Trial
Storage
Powder -80°C 2 years
  -20°C 1 year
In solvent -80°C 6 months
  -20°C 1 month
Solvent & Solubility
In Vitro: 

H2O : ≥ 30.2 mg/mL (33.59 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.1123 mL 5.5617 mL 11.1235 mL
5 mM 0.2225 mL 1.1123 mL 2.2247 mL
10 mM 0.1112 mL 0.5562 mL 1.1123 mL
*Please refer to the solubility information to select the appropriate solvent.
References
Kinase Assay
[1]

Competition assays using purified canine ACE are determined using a fixed concentration of the substrate Hip-His-Leu (1 mM) and varying the concentrations of the competing agents [Lisinopril (0.1 to 100 nM), Angiotensin (1-7) (10 nM to 10 μM), or Sar1, Thr8-Ang II (10 nM to 10 μM)]. Inhibitory constants (IC50) are determined from the respective competition curves. To study the effect of Angiotensin (1-7) on BK metabolism in intact coronary rings, 125I-[Tyr0]-BK (final concentration of 1 nM) is added to the tubes containing three rings preincubated with 1 mL Krebs' buffer and aerated with 95% O2 and 5% CO2 at 37°C. Lisinopril (2 μM), Angiotensin (1-7) (2 μM), or Krebs' buffer as control are added to the rings 10 minutes before addition of the radiolabeled BK. Aliquots of the incubation medium are removed at 5, 10, and 20 minutes and diluted with 1% HFBA to inhibit peptidase activity[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[2]

500 μM Methylglyoxal is incubated with 100 μM BSA dissolved in phosphate buffered saline (PBS) for 24 hours, then washed on 10 kDa filters to remove excess methyl glyoxal, reconstituted with DMEM/F12 serum free media and passed through a 0.2 μmicron filter. TGF-β (5 ng/mL) is prepared to treat cells in a subset of experiments. Cells are co-treated with one or combinations of the following: Angiotensin (1-7) (100 nM), D-Ala7-Ang-(1-7) (10 μM), ERK1/2 kinase inhibitor, PD 98059 (1 μM), TGF-β receptor kinase inhibitor; SB525334 (1 μM), the AT1 receptor antagonist Losartan (1 μM), the renin inhibitor Aliskerin (1 μM) and the ACE inhibitor Lisinopril (1 μM)[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[3][4]

Mice[3]
Male and female BALB/c mice (1:1 ratio, 6-10 weeks old, mean weight 20 g.) are used. Angiotensin fragment 1-7 acetate salt hydrate (Ang 1-7) is dissolved in 0.9% saline (vehicle) at 1 mg/mL and stored at -80°C. Various doses (0.01, 0.06, 0.1, 0.3 and 1 mg/kg) are freshly prepared from the stock each day of the experiment, and administered to mice by daily intra-peritoneal (i.p) injections in a volume of 500 μL per injection, either before (prophylactic approach) or after (treatment approach) DSS treatment. A779 (MAS-1 R antagonist) is similarly dissolved in distilled water at 1 mg/mL and stored at -80°C. A freshly prepared dose of 1 mg/kg is administered to a second group of mice by daily i.p injections in a volume of 500 μL daily (for 4 days) along with colitis induction (prophylactic approach). A third group of mice receive DSS containing water and daily i.p injections of 0.9% saline (vehicle). The fourth group receive DSS containing water along with daily i.p injections with Dexamethasone (DEX) at doses of 0.01-1.0 mg/kg or its vehicle (0.9% saline) (prophylactic approach).
Rats[4]
Twenty six ovariectomized female Wistar rats weighing 200±20 g are used. Angiotensin (1-7) is administered intravenously by a microsyringe pump at two different continuous doses of 100 and 300 ng/kg/min after antagonist/saline infusion. Each dose is infused for 15 min; and MAP, RPP, and RBF are recorded during Angiotensin (1-7) infusion and the last 3-5 min of each dose measured as “response to Angiotensin (1-7) infusion”. During Angiotensin (1-7) infusion, RPP is sustained at pre-Ang1-7 infusion levels via an adjustable aortic clamp. At the end of the experiment, the rats are humanely killed by anesthetic overdose, and the left kidneys are removed and weighed immediately.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

899.00

Formula

C₄₁H₆₂N₁₂O₁₁

CAS No.

51833-78-4

Sequence

Asp-Arg-Val-Tyr-Ile-His-Pro

Sequence Shortening

DRVYIHP

SMILES

O=C(N(CCC1)[[email protected]@H]1C(O)=O)[[email protected]@H](NC([[email protected]@]([[email protected]@H](C)CC)([H])NC([[email protected]@H](NC([[email protected]](C(C)C)NC([[email protected]](CCCNC(N)=N)NC([[email protected]@H](N)CC(O)=O)=O)=O)=O)CC2=CC=C(O)C=C2)=O)=O)CC3=CNC=N3

Shipping

Room temperature in continental US; may vary elsewhere

Purity: 99.61%

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Angiotensin 1-7
Cat. No.:
HY-12403
Quantity:

Angiotensin 1-7

Cat. No.: HY-12403